Including results for reata investor relations
Search only for reta investor relations
Reata Pharmaceuticals has been acquired by Biogen.
Jul 28, 2023 · Biogen will host an investor call on July 28, 2023, at 9:00 a.m. ET. The conference call will be accessible through the Investors section of ...
Investor Relations: Vinny Jindal. Vice President, Strategy. (469) 374-8721. ir@reatapharma.com. Media: Matt Middleman, M.D.. LifeSci Public Relations. (646) 627 ...
Jun 1, 2023 · Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
People also ask
Did Biogen acquire Reata?
How much did Biogen pay for Reata?
Is bardoxolone approved by the FDA?
Who acquired Biogen?
Reata Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation · SA ... Reata Pharmaceuticals (RETA) Investor Presentation - Slideshow · SA ...
Missing: relations | Show results with:relations
Learn how to use EDGAR to research public filings by public companies, mutual funds, ETFs, some annuities, and more. Before you Invest, Investor.gov. Get ...
Missing: relations | Show results with:relations
Reata Pharmaceuticals Inc - Class A (NASDAQ:RETA) institutional ownership structure shows current positions in the company by institutions and funds, as well as ...
The Investor Relations website contains information about Taro Pharmaceutical's business for stockholders, potential investors, and financial analysts.
Missing: reta | Show results with:reta
May 2, 2023 · Reata Pharmaceuticals, Inc. (972) 865-2219 https://www.reatapharma.com/. Investor Relations & Media Relations: John Hunter ir@reatapharma ...
May 6, 2019 · The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with this event. View as PDF. INVESTOR PRESENTATION.
Missing: relations | Show results with:relations